Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
Open Access
- 14 October 2022
- journal article
- letter
- Published by Frontiers Media SA in Transplant International
- Vol. 35, 10693
Abstract
Over 30% of patients with immunoglobulin A Nephropathy (IgAN) progress to end stage Chronic Kidney Disease and once they are transplanted, up to 50% suffer IgAN recurrence. Based on the gut-kidney axis, targeted-release-formulation budesonide (TRF-budesonide) has proved proteinuria reduction and estimated glomerular filtration rate (eGFR) benefit. We retrospectively assessed 14 patients with IgAN (5 kidney transplants and 9 native kidneys) treated with a median dose of 9mg/day of TRF-budesonide between December 2017 and January 2022 in our Nephrology department. Mean age of 46±17.21 years. All kidney transplants and 6/9 (66.7%) patients with native kidneys were already receiving renin-angiotensin system (RAS) inhibitors. The relative decrease of proteinuria was of -33.1% and -54.6% after 3 and 6 months of TRF-budesonide treatment (p<0.05 and p<0.05, respectively). If kidney transplant were evaluated separately, proteinuria did also significantly decrease (-26.7%) after 3 months of treatment (p<0.05). CKD-EPI, serum creatinine and haematuria were not modified. No clinical relevant adverse events were observed throughout the follow-up. TRF-budesonide significantly reduced proteinuria, maintained eGFR levels and was well tolerated during 24 months of follow-up in patients with IgAN. Therefore, TRF-budesonide may represent a new approach to IgAN treatment in both patients with native and kidney transplant.Keywords
This publication has 10 references indexed in Scilit:
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular DiseasesKidney International, 2021
- Outcome of 313 Czech Patients With IgA Nephropathy After Renal TransplantationFrontiers in Immunology, 2021
- POS-830 NEFECON FOR THE TREATMENT OF IgA NEPHROPATHY IN PATIENTS AT RISK OF PROGRESSING TO END-STAGE RENAL DISEASE: THE NEFIGARD PHASE 3 TRIAL RESULTSKidney International Reports, 2021
- Budesonide versus systemic corticosteroids in IgA NephropathyMedicine, 2020
- Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonideSaudi Journal of Kidney Diseases and Transplantation, 2020
- Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomesKidney International, 2017
- Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trialThe Lancet, 2017
- New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuriaNephrology Dialysis Transplantation, 2011
- The incidence of primary glomerulonephritis worldwide: a systematic review of the literatureNephrology Dialysis Transplantation, 2010
- Remission of Proteinuria Improves Prognosis in IgA NephropathyJournal of the American Society of Nephrology, 2007